Regulating glucose metabolism using nanomedicines for cancer therapy

Ming Tang1, Xiangling Ren2, Changhui Fu3

  • 1College of Material Science and Chemical Engineering, Harbin Engineering University, Harbin 150001, China and Laboratory of Controllable Preparation and Application of Nanomaterials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China. mengxw@mail.ipc.ac.cn and Key Laboratory of Super Light Material and Surface Technology Ministry of Education, Harbin Engineering University, Harbin 150001, China and CAS Key Laboratory of Cryogenics, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China.

Insights

Regulating glucose metabolism with nanomedicines offers new cancer treatment strategies. This review explores targeting tumor cell energy pathways for enhanced therapies like chemotherapy and hyperthermia.

Area of Science:

  • Biochemistry
  • Oncology
  • Nanotechnology

Background:

  • Glucose metabolism is crucial for tumor cell growth and proliferation.
  • Targeting glucose metabolism presents significant opportunities for cancer treatment.
  • Nanomedicines have advanced the regulation of glucose metabolism pathways for cancer therapy.

Purpose of the Study:

  • To review the role of glucose metabolism in cancer.
  • To discuss nanomedicine strategies for regulating glucose metabolism in various tumor resistance contexts.
  • To present future prospects and challenges in developing nanoagents for cancer treatment.

Main Methods:

  • Review of cell energy supply pathways (aerobic and anaerobic).
  • Discussion of recent research on regulating glucose metabolism against tumor resistance (heat, drug, hypoxia).
  • Analysis of multifunctional nanoagents for combined therapies.

Main Results:

  • Glucose metabolism pathways are key targets for cancer therapy.
  • Nanomedicines show promise in overcoming tumor resistance by modulating glucose metabolism.
  • Multifunctional nanoagents can integrate various therapeutic modalities.

Conclusions:

  • Regulating glucose metabolism via nanomedicines is a promising avenue for cancer treatment.
  • Further development of nanoagents is needed to address challenges in efficacy and resistance.
  • Integrating therapies like chemotherapy and hyperthermia holds potential for improved outcomes.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
496
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
378
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
338
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
5.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K